Reaching Others University at Buffalo - The State University of New York
Skip to Content
William                        Jusko

William J. Jusko 

Department of Pharmaceutical Sciences

Department Chair, Distinguished Professor

 
top-left cornertop-right corner
Professional Summary:

Research interests are in theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer. With Drs. Richard Almon and Debra DuBois, Dr. Jusko delves into the pharmacogenomics of diverse effects of corticosteroids and has evolved advanced mathematical models of receptor/gene-mediated responses. They have characterized the effects of corticosteroids on hepatic and muscle enzymes and tissue responses and have evolved advanced PK/PD models for cascade-type processes. Dr. Jusko has developed mechanism-based pharmacokinetic, pharmacodynamic, and disease progression models and computational methods describing the action of various drugs and utilizes mathematical models of drug action to determine optimal dosage regimens diverse drugs.

Education and Training:
  • PhD, State University of New York at Buffalo (1970)
  • , State University of New York at Buffalo (1965)
  • MB, BCh, BAO, Salamanca High School (1960)
Employment:
  • Director, Clinical Pharmacokinetics Laboratory (1972–1981)
  • Visiting Scientist (1978–1979)
  • Assistant Professor of Pharmaceutics (1972–1974)
  • Assistant Professor of Pharmacology (1970–1972)
  • Research Pharmacologist (1969–1972)
  • Research Associate (1969–1972)
  • Research Assistant (1962–1969)
  • Pharmacist (1966–1968)
  • Hospital Pharmacist (1962–1966)
Awards and Honors:
  • Sheiner-Beal Pharmacometrics Award (2013)
  • Advisor: AAPS Graduate Student Award in PPDM - Hoi Kei Lon (2012)
  • 2012 Distinguished Investigator Award (2012)
  • ACoP Award, Received the first ACoP Leadership Award at the American Conference on Pharmacometrics Meeting, San Diego, CA (2011)
  • AAPS Meritorious Manuscript Award (2008)
  • Distinguished Professor (2008)
  • Paul Ehrlich Magic Bullet Lifetime Achievement Award (2008)
  • Distinguished Professor (2007)
  • Swintosky Distinguished Lecturer (2006)
  • Volwiler Research Achievement Award (2005)
  • MERIT Award (2005)
  • Roland T. Lakey Award Lecture (2003)
  • ISI Most Highly Cited List in Pharmacology (2003)
  • Chancellor's Award (2003)
  • Sustained Achievement Award (2002)
  • John G. Wagner Lectureship (1999)
  • Research Achievement Award in PPDM, AAPS (1998)
  • Kosciusko Award (1996)
  • Faculty Exchange Scholar (1990)
  • Distinguished Service Award (1989)
  • Fellow (1989)
  • Russell R. Miller Award (1988)
  • Rawls-Palmer Award (1987)
  • Doctor Honoris Causae (1987)
  • Citizen of the Year (1987)
  • Fellow (1986)
  • Fellow (1985)
  • Fellow (1980)
  • Rorer Award (1980)
  • Fulbright-Hays Award to lecture/research in Milan, Italy (1978)
  • University Professor (1977)
  • Who's Who (various venues)
  • American Men and Women of Science

Research Expertise:
  • : Theoretical, basic, and clinical aspects of the PK/PD of immunosuppressive agents including corticosteroids, sirolimus, and tacrolimus
  • : Pharmacogenomics of diverse effects of corticosteroids and the development of models of receptor/gene-mediated responses
  • : Mechanism-based PK/PD models and computational methods describing the action of various drugs including PK/PD models of hematopoiesis characterizing stimulatory effects of growth factors and cytotoxicity of anticancer agents.
  • : Development of a compendium with comparison of the array of relevant mechanism-based PK/PD models
  • : Development of indirect response models with a precursor compartment including the occurrence of feedback alterations; evolution of extended indirect lifespan models for application to natural cell responses including effects such as bone marrow stimulation and/or cytotoxicity
  • : Detailed characterization of nonlinear and time-dependent transduction models which may be applied to numerous membrane receptor (e.g., G-protein) mediated responses.
Grants and Sponsored Research:
  • January 1998–December 2011
    Mathematical Models in Pharmacodynamics
    National Institutes of Health
    Role: Principal Investigator
Patents:
  • Novel Method of Treatment (1999)

Evaluative Studies and Case Reports:
Journal Articles:
  • Rohatagi S, Carrothers TJ, Jin J, Jusko WJ, Khariton T, Walker J, Truitt K, Salazar DE. Model-Based Development of a PPAR{gamma} Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs. J Clin Pharmacol. 2008; 48(12).
  • Landersdorfer CB, Dubois DC, Almon RR, Jusko WJ. Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats. J Pharmacol Exp Ther. 2008.
  • Almon RR, Yang E, Lai W, Androulakis IP, Ghimbovschi S, Hoffman EP, Jusko WJ, Dubois DC. Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2008; 295(4).
  • Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime Against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008.
  • Earp JC, Pyszczynski NA, Molano DS, Jusko WJ. Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis. Biopharm Drug Dispos. 2008; 29(6).
  • Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther. 2008; 326(2).
  • Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther. 2008; 326(2).
  • Yao Z, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2008; 97(7).
  • Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol. 2008; 62(1).
  • Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008; 83(6).
  • Hazra A, Pyszczynski NA, DuBois DC, Almon RR, Jusko WJ. Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats. Pharm Res. 2008; 25(4).
  • Yao Z, Hoffman EP, Ghimbovschi S, Dubois DC, Almon RR, Jusko WJ. Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm. 2008; 5(2).
  • Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008; 47(7).
  • Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J Clin Pharmacol. 2008; 48(1).
  • Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007; 34(6).
  • Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J Clin Pharmacol. 2007.
  • Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ. Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn. 2007; 34(5).
  • Yao Z, Dubois DC, Almon RR, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2007.
  • Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm Drug Dispos. 2007; 28(6).
  • Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007; 35(9).
  • Hong Y, Mager DE, Blum RA, Jusko WJ. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharm Res. 2007; 24(6).
  • Yang E, Simcha D, Almon RR, Dubois DC, Jusko WJ, Androulakis IP. Context specific transcription factor prediction. Ann Biomed Eng. 2007; 35(6).
  • Hazra A, DuBois DC, Almon RR, Jusko WJ. Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling. J Pharmacokinet Pharmacodyn. 2007; 34(3).
  • Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clin Cancer Res. 2007; 13(7).
  • Hazra A, Krzyzanski W, Jusko WJ. Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn. 2006; 33(6).
  • Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther. 2006; 319(3).
  • Krzyzanski W, Dmochowski J, Matsushima N, Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn. 2006; 33(5).
  • Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, Jusko WJ. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos. 2006; 34(9).
  • Qu J, Jusko WJ, Straubinger RM. Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem. 2006; 78(13).
  • Qu J, Jusko WJ, Straubinger RM. Utility of cleavable isotope-coded affinity-tagged reagents for quantificationof low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Analytical Chemistry. 2006; 78(13).
  • Yao Z, DuBois DC, Almon RR, Jusko WJ. Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res. 2006; 23(4).
  • Krzyzanski W, Woo S, Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn. 2006; 33(2).
  • Yao Z, Krzyzanski W, Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn. 2006; 33(2).
  • Samtani MN, Pyszczynski NA, Dubois DC, Almon RR, Jusko WJ. Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy. J Pharmacol Exp Ther. 2006; 317(1).
  • Samtani MN, Pyszczynski NA, Dubois DC, Almon RR, Jusko WJ. Modeling glucocorticoid-mediated fetal lung maturation: II. Temporal patterns of gene expression in fetal rat lung. J Pharmacol Exp Ther. 2006; 317(1).
  • Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G, Spratlin VE, Jann MW. Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study. Mol Diagn Ther. 2006; 10(2).
  • Qu J, Jusko W, Straubinger R. Quantitation of methylprednisolone-responsive changes in low-copy protein expression using liquid chromatography/tandem mass spectroscopy and cleavable isotope coded affinity tags. Analytical Chemistry. 2006.
  • Perez-Ruixo JJ, Kimko HC, Chow AT, Piotrovsky V, Krzyzanski W, Jusko WJ. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn. 2005; 32(5-6).
  • Gordi T, Xie R, Jusko WJ. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol. 2005; 60(6).
  • Almon RR, Lai W, DuBois DC, Jusko WJ. Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab. 2005; 289(5).
  • Samtani MN, Jusko WJ. Stability of dexamethasone sodium phosphate in rat plasma. Int J Pharm. 2005; 301(1-2).
  • Samtani MN, Lohle M, Grant A, Nathanielsz PW, Jusko WJ. Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Drug Metab Dispos. 2005; 33(8).
  • Samtani MN, Jusko WJ. Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration. Biopharm Drug Dispos. 2005; 26(3).
  • Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ. Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. J Pharm Sci. 2005; 94(3).
  • Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneousadministration in monkeys. Pharm Res. 2005; 22(1).
  • Almon RR, Dubois DC, Jin JY, Jusko WJ. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol. 2005; 184(1).
  • Samtani MN, Schwab M, Nathanielsz PW, Jusko WJ. Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharm Res. 2004; 21(12).
  • Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn. 2004; 31(5).
  • Kamal MA, Jusko WJ. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. J Clin Pharmacol. 2004; 44(9).
  • Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004; 44(9).
  • Lepist EI, Jusko WJ. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther. 2004; 27(4).
  • Lepist EI, Jusko WJ. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis.. J Vet Pharmacol Ther. 2004; 27(4).
  • Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by hypericum perforatum. Blood. 2004; 104(4).
  • Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes.. Clin Pharmacol Ther. 2004; 76(1).
  • Almon RR, DuBois DC, Piel WH, Jusko WJ. The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.. Pharmacogenomics. 2004; 5(5).
  • Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther. 2004; 76(1).
  • Almon RR, DuBois DC, Piel WH, Jusko WJ. The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics. 2004; 5(5).
  • Jin JY, DuBois DC, Almon RR, Jusko WJ. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther. 2004; 309(1).
  • Jin JY, DuBois DC, Almon RR, Jusko WJ. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver.. J Pharmacol Exp Ther. 2004; 309(1).
  • Samtani MN, Schwab M, Nathanielsz PW, Jusko WJ. Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma.. J Pharm Sci. 2004; 93(3).
  • Chen J, Zhao P, Massaro D, Clerch LB, Almon RR, DuBois DC, Jusko WJ, Hoffman EP. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface.. Nucleic Acids Res. 2004; 32 Da.
  • Chen J, Zhao P, Massaro D, Clerch LB, Almon RR, DuBois DC, Jusko WJ, Hoffman EP. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res. 2004; 32(Datab).
  • Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John‘s wort on the pharmacokinetics and protein bindingof imatinib mesylate. Pharmacotherapy. 2004; 24(11).
  • Smith PF, Bullock JM, Booker BM, Haas CE, Berenson C, Jusko WJ. Influence of St. John’s Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate. Pharmacotherapy. 2004; 24(11).
  • Almon RR, DuBois DC, Pearson KE, Stephan DA, Jusko WJ. Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver.. Funct Integr Genomics. 2003; 3(4).
  • Almon RR, Chen J, Snyder G, DuBois DC, Jusko WJ, Hoffman EP. In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR).. Pharmacogenomics. 2003; 4(6).
  • Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics.. J Clin Pharmacol. 2003; 43(11).
  • Jin JY, Almon RR, DuBois DC, Jusko WJ. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays.. J Pharmacol Exp Ther. 2003; 307(1).
  • Mager DE, Moledina N, Jusko WJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation.. J Pharm Sci. 2003; 92(7).
  • Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.. J Pharmacol Exp Ther. 2003; 306(1).
  • Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-Beta1a Following Intravenous and Subcutaneous Dosing in Monkeys. J Pharmacol Exp Ther. 2003; 306(1).
  • Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther. 2003; 306(1).
  • Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.. J Pharm Sci. 2003; 92(5).
  • Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models.. Drug Metab Dispos. 2003; 31(5).
  • Mager DE, Pyszczynski NA, Jusko WJ. Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids.. J Pharm Sci. 2003; 92(4).
  • Mager DE, Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.. J Pharm Sci. 2002; 91(11).
  • Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.. Pharm Res. 2002; 19(10).
  • Krzyzanski W, Jusko WJ. Multiple-pool cell lifespan model of hematologic effects of anticancer agents.. J Pharmacokinet Pharmacodyn. 2002; 29(4).
  • Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation.. Br J Clin Pharmacol. 2002; 53(5).
  • Chakraborty A, Jusko WJ. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation.. J Pharm Sci. 2002; 91(5).
  • Li H, Meno-Tetang GM, Chiba K, Arima N, Heining P, Jusko WJ. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.. J Pharmacol Exp Ther. 2002; 301(2).
  • Almon RR, DuBois DC, Brandenburg EH, Shi W, Zhang S, Straubinger RM, Jusko WJ. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis.. J Pharmacokinet Pharmacodyn. 2002; 29(2).
  • Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats.. J Pharmacokinet Pharmacodyn. 2002; 29(1).
  • Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats.. J Pharmacol Exp Ther. 2002; 300(1).
  • Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.. J Pharmacokinet Pharmacodyn. 2001; 28(6).
  • Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems.. Clin Pharmacol Ther. 2001; 70(3).
  • Wyska E, Jusko WJ. Approaches to pharmacokinetic/ pharmacodynamic modeling during pregnancy.. Semin Perinatol. 2001; 25(3).
  • Gobburu JV, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses.. Adv Drug Deliv Rev. 2001; 46(1-3).
  • Krzyzanski W, Jusko WJ. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.. J Pharmacokinet Biopharm. 2001; 28(1).
  • Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for drug labeling.. Clin Pharmacol Ther. 2000; 68(6).
  • Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.. Biopharm Drug Dispos. 2000; 21(2).
  • Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.. J Pharmacol Exp Ther. 2000; 292(2).
  • Krzyzanski W, Chakraborty A, Jusko WJ. Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models.. Chronobiol Int. 2000; 17(1).
  • Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells.. J Pharmacokinet Biopharm. 1999; 27(5).
  • Fasanmade AA, Jusko WJ. Immunodynamics of methylprednisolone induced T-cell trafficking and deactivation using whole blood lymphocyte proliferation techniques in the rat.. Biopharm Drug Dispos. 1999; 20(5).
  • Sun YN, Lee HJ, Almon RR, Jusko WJ. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.. J Pharmacol Exp Ther. 1999; 289(3).
  • Imani S, Jusko WJ, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers.. Pediatr Transplant. 1999; 3(2).
  • Sun YN, McKay LI, DuBois DC, Jusko WJ, Almon RR. Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism.. J Pharmacol Exp Ther. 1999; 288(2).
  • Chakraborty A, Krzyzanski W, Jusko WJ. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods.. J Pharmacokinet Biopharm. 1999; 27(1).
  • Ferron GM, Pyszczynski NA, Jusko WJ. Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.. J Pharmacokinet Biopharm. 1999; 27(1).
  • Meno-Tetang GM, Gobburu JV, Jusko WJ. Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats.. J Pharm Sci. 1999; 88(1).
  • Meno-Tetang GM, Hon YY, Van Wart S, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.. Drug Metabol Drug Interact. 1999; 15(1).
  • Krzyzanski W, Jusko WJ. Caution in use of empirical equations for pharmacodynamic indirect response models.. J Pharmacokinet Biopharm. 1998; 26(6).
  • Sun YN, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.. J Pharmacokinet Biopharm. 1998; 26(6).
  • Ferron GM, Jusko WJ. Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits.. Pharm Res. 1998; 15(12).
  • Krzyzanski W, Jusko WJ. Note: caution in use of empirical equations for pharmacodynamic indirect response models. J Pharmacokinet Biopharm. 1998; 26(6).
  • Flores-Murrieta FJ, Ko HC, Flores-Acevedo DM, López-Muñoz FJ, Jusko WJ, Sale ME, Castañeda-Hernández G. Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach.. J Pharmacokinet Biopharm. 1998; 26(5).
  • Krzyzanski W, Jusko WJ. Characterization of pharmacodynamic recession slopes for direct and indirect response models.. J Pharmacokinet Biopharm. 1998; 26(4).
  • Krzyzanski W, Jusko WJ. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.. J Pharmacokinet Biopharm. 1998; 26(4).
  • Gobburu JV, Tenhoor C, Rogge MC, Frazier DE, Thomas D, Benjamin C, Hess DM, Jusko WJ. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.. J Pharmacol Exp Ther. 1998; 286(2).
  • Ferron GM, Jusko WJ. Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays.. J Pharmacol Exp Ther. 1998; 286(1).
  • Sun YN, Jusko WJ. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.. J Pharm Sci. 1998; 87(6).
  • Sun YN, DuBois DC, Almon RR, Jusko WJ. Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.. J Pharmacokinet Biopharm. 1998; 26(3).
  • Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.. Transplantation. 1998; 65(9).
  • Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats.. Drug Metab Dispos. 1998; 26(1).
  • Krzyzanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamic response.. J Pharm Sci. 1998; 87(1).
  • Ferron GM, Conway WD, Jusko WJ. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (rapamycin) determination.. J Chromatogr B Biomed Sci Appl. 1997; 703(1-2).
  • Ko HC, Jusko WJ, Ebling WF. Nonlinear perpendicular least-squares regression in pharmacodynamics.. Biopharm Drug Dispos. 1997; 18(8).
  • McKay LI, DuBois DC, Sun YN, Almon RR, Jusko WJ. Corticosteroid effects in skeletal muscle: gene induction/receptor autoregulation.. Muscle Nerve. 1997; 20(10).
  • Krzyzanski W, Jusko WJ. Application of moment analysis to the sigmoid effect model for drug administered intravenously.. Pharm Res. 1997; 14(7).
  • Chow FS, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion.. Drug Metab Dispos. 1997; 25(5).
  • Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients.. Clin Pharmacol Ther. 1997; 61(4).
  • Krzyzanski W, Jusko WJ. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.. J Pharmacokinet Biopharm. 1997; 25(1).
  • Cheng H, Gong Y, Jusko WJ. A computer program using disposition decomposition analysis in pharmacodynamics.. Biopharm Drug Dispos. 1997; 18(1).
  • Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses.. J Clin Pharmacol. 1996; 36(10).
  • Meno-Tetang GM, Hon YY, Jusko WJ. Synergistic interaction between dehydroepiandrosterone and prednisolone in the inhibition of rat lymphocyte proliferation.. Immunopharmacol Immunotoxicol. 1996; 18(3).
  • Cheng H, Jusko WJ. Disposition decomposition analysis for pharmacodynamic modeling of the link compartment.. Biopharm Drug Dispos. 1996; 17(2).
  • Mishina EV, Jusko WJ. Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics.. Pharm Res. 1996; 13(1).
  • Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring.. Ther Drug Monit. 1995; 17(6).
  • DuBois DC, Xu ZX, McKay L, Almon RR, Pyszcznski N, Jusko WJ. Differential dynamics of receptor down-regulation and tyrosine aminotransferase induction following glucocorticoid treatment.. J Steroid Biochem Mol Biol. 1995; 54(5-6).
  • Jusko WJ. Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids.. Toxicology. 1995; 102(1-2).
  • Fasanmade AA, Jusko WJ. Optimizing whole blood lymphocyte proliferation in the rat.. J Immunol Methods. 1995; 184(2).
  • Szefler SJ, Bender BG, Jusko WJ, Lanier BQ, Lemanske RF, Skoner DP, Stempel DA. Evolving role of theophylline for treatment of chronic childhood asthma.. J Pediatr. 1995; 127(2).
  • Lee MJ, Straubinger RM, Jusko WJ. Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats.. Pharm Res. 1995; 12(7).
  • Ko HC, Almon RR, Jusko WJ. Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats.. Pharm Res. 1995; 12(6).
  • Fasanmade AA, Jusko WJ. An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs.. Drug Metab Dispos. 1995; 23(5).
  • Lee MJ, Pyszczynski N, Jusko WJ. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation.. Immunopharmacol Immunotoxicol. 1995; 17(2).
  • Xu ZX, Sun YN, DuBois DC, Almon RR, Jusko WJ. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver.. J Pharmacokinet Biopharm. 1995; 23(2).
  • Xu ZX, Lee MJ, Blum RA, Jusko WJ. Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking.. Pharm Res. 1995; 12(3).
  • Fasanmade AA, Jusko WJ. Effect of halofantrine and its desbutyl metabolite on lymphocyte proliferation dynamics.. Life Sci. 1995; 57(14).
  • Ko HC, Jusko WJ. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.. Pharmacotherapy. 1995; 15(4).
  • Milsap RL, Jusko WJ. Pharmacokinetics in the infant.. Environ Health Perspect. 1994; 102 S.
  • Mishina EV, Binder J, Kupiec-Weglinski JW, Jusko WJ. Effect of liposomal methylprednisolone on heart allograft survival and immune function in rats.. J Pharmacol Exp Ther. 1994; 271(2).
  • Cheng H, Gillespie WR, Jusko WJ. Mean residence time concepts for non-linear pharmacokinetic systems.. Biopharm Drug Dispos. 1994; 15(8).
  • Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects.. Clin Pharmacol Ther. 1994; 56(4).
  • Binder J, Mishina EV, Jusko WJ, Kupiec-Weglinski JW. Prolongation of cardiac allograft survival in rats by liposome-encapsulated methylprednisolone.. Transplantation. 1994; 58(5).
  • Piekoszewski W, Chow FS, Jusko WJ. Inhibition of phytohaemagglutinin-induced lymphocyte proliferation by immunosuppressive drugs: use of whole blood culture.. Immunopharmacol Immunotoxicol. 1994; 16(3).
  • Jusko WJ, Pyszczynski NA, Bushway MS, D'Ambrosio R, Mis SM. Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma.. J Chromatogr B Biomed Appl. 1994; 658(1).
  • D'Ambrosio R, Girzaitis N, Jusko WJ. Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction.. Ther Drug Monit. 1994; 16(3).
  • Mishina EV, Jusko WJ. Inhibition of rat splenocyte proliferation with methylprednisolone: in vivo effect of liposomal formulation.. Pharm Res. 1994; 11(6).
  • Cheng H, Yu C, Jusko WJ. An algorithm and computer program for calculating the mean transit time and distribution rate parameters of generated metabolites undergoing linear tissue distribution and linear or non-linear central elimination.. Biopharm Drug Dispos. 1994; 15(4).
  • Garg V, Jusko WJ. Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats.. J Pharm Sci. 1994; 83(5).
  • Garg V, Hon YY, Jusko WJ. Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats.. Pharm Res. 1994; 11(4).
  • Mishina EV, Jusko WJ. Selected tissue distribution of liposomal methylprednisolone in rats.. Res Commun Chem Pathol Pharmacol. 1994; 84(1).
  • Piekoszewski W, Chow FS, Jusko WJ. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits.. J Pharmacol Exp Ther. 1994; 269(1).
  • Jusko WJ. Receptor-mediated pharmacodynamics of corticosteroids, In: Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis. Prog Clin Biol Res. 1994; 387.
  • Wald JA, Jusko WJ. Prednisolone pharmacodynamics: leukocyte trafficking in the rat.. Life Sci. 1994; 55(19).
  • Jusko WJ. Receptor-mediated pharmacodynamics of corticosteroids. Prog Clin Biol Res. 1994; 387.
  • Cheng H, Jusko WJ. Pharmacokinetics of reversible metabolic systems.. Biopharm Drug Dispos. 1993; 14(9).
  • Milad MA, Jusko WJ. Pharmacodynamic interpretation of adrenocorticotropin stimulation tests.. Ann Pharmacother. 1993; 27(10).
  • Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, Jusko WJ. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.. Clin Pharmacol Ther. 1993; 54(4).
  • D'Ambrosio R, Girzaitis N, Jusko WJ. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood.. Ther Drug Monit. 1993; 15(5).
  • Mishina EV, Straubinger RM, Pyszczynski NA, Jusko WJ. Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation.. Pharm Res. 1993; 10(10).
  • Jusko WJ, Milsap RL. Pharmacokinetic principles of drug distribution in saliva.. Ann N Y Acad Sci. 1993; 694.
  • Chow AT, Meek PD, Jusko WJ. High-pressure liquid chromatographic assay of theophylline in dog feces following oral administration of sustained-release products.. J Pharm Sci. 1993; 82(9).
  • Ludwig EA, Kong AN, Camara DS, Jusko WJ. Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease.. J Clin Pharmacol. 1993; 33(9).
  • Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses.. J Pharmacokinet Biopharm. 1993; 21(4).
  • Pleyer U, Lutz S, Jusko WJ, Nguyen KD, Narawane M, Rückert D, Mondino BJ, Lee VH, Nguyen K. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye.. Invest Ophthalmol Vis Sci. 1993; 34(9).
  • DuBois DC, Almon RR, Jusko WJ. Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards.. Anal Biochem. 1993; 210(1).
  • Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans.. J Pharm Sci. 1993; 82(3).
  • Cheng H, Jusko WJ. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism.. Pharm Res. 1993; 10(1).
  • Lew KH, Jusko WJ. Pharmacodynamic modeling of cortisol suppression from fluocortolone.. Eur J Clin Pharmacol. 1993; 45(6).
  • Piekoszewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.. Drug Metab Dispos. 1993; 21(4).
  • Fisher LE, Ludwig EA, Jusko WJ. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes.. J Pharmacokinet Biopharm. 1992; 20(4).
  • Wald JA, Jusko WJ. Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone.. Pharm Res. 1992; 9(8).
  • Haughey DB, Jusko WJ. Receptor-mediated methylprednisolone pharmacodynamics in rats: steroid-induced receptor down-regulation.. J Pharmacokinet Biopharm. 1992; 20(4).
  • Dove AM, Szefler SJ, Hill MR, Jusko WJ, Larsen GL, Accurso FJ. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.. J Pediatr. 1992; 120(5).
  • Haughey DB, Jusko WJ. Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat.. J Pharm Sci. 1992; 81(2).
  • Jusko WJ, Kung LP, Schmelter RF. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients. Targeted Diagn Ther. 1992; 6.
  • Jusko WJ, D'Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood.. Transplant Proc. 1991; 23(6).
  • Haughey DB, Jusko WJ. Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics.. J Pharmacol Exp Ther. 1991; 259(2).
  • Shum L, Jusko WJ. Verofylline pharmacokinetics in dietary-induced obese rats: role of fat mass and protein binding in determining volume of distribution.. Xenobiotica. 1991; 21(11).
  • Wald JA, Salazar DE, Chen HY, Jusko WJ. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.. J Pharmacokinet Biopharm. 1991; 19(5).
  • Garg V, Jusko WJ. Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography.. J Chromatogr. 1991; 567(1).
  • Kong AN, Jusko WJ. Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination.. J Pharm Sci. 1991; 80(5).
  • Cheng HY, Jusko WJ. Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.. Pharm Res. 1991; 8(4).
  • Cheng HY, Jusko WJ. Drug redistribution and mean transit time concepts for nonlinear pharmacokinetic systems.. Biopharm Drug Dispos. 1991; 12(1).
  • Cheng HY, Jusko WJ. Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism.. Pharm Res. 1990; 7(10).
  • Chow AT, Jusko WJ. Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose.. J Pharm Sci. 1990; 79(10).
  • Huang ML, Jusko WJ. Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats.. J Pharmacokinet Biopharm. 1990; 18(5).
  • Cheng H, Jusko WJ. Constant-rate intravenous infusion methods for estimating steady-state volumes of distribution and mean residence times in the body for drugs undergoing reversible metabolism.. Pharm Res. 1990; 7(6).
  • Nichols AI, Jusko WJ. Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen.. J Pharmacokinet Biopharm. 1990; 18(3).
  • Jusko WJ. Corticosteroid pharmacodynamics: models for a broad array of receptor-mediated pharmacologic effects.. J Clin Pharmacol. 1990; 30(4).
  • Cheng HY, Jusko WJ. Effects of variation in drug elimination on five methods for assessing zero-order drug absorption rates.. Pharm Res. 1990; 7(1).
  • Cheng HY, Jusko WJ. Mean residence times of multicompartmental drugs undergoing reversible metabolism.. Pharm Res. 1990; 7(1).
  • Murata R, Haughey DB, Jusko WJ. Effects of thyroid dysfunction on prednisolone and prednisone interconversion and disposition in the rat.. Drug Metab Dispos. 1990; 18(4).
  • Jusko WJ, Kung LP, Schmelter RF. Immunopharmacokinetics of 111In-CYT-103 in Ovarian Cancer Patients, In: Diagnosis of Colorectal and Ovarian Carcinoma: Application of Immunoscintigraphic Technology. Targeted Diagn Ther. 1990; 6.
  • Kong AN, Jungbluth GL, Pasko MT, Beam TR, Jusko WJ. Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass.. Pharmacotherapy. 1990; 10(1).
  • Tornatore KM, Morse GD, Jusko WJ, Walshe JJ. Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. Transplantation. 1989; 48(6).
  • Kong AN, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E, Jusko WJ. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.. Clin Pharmacol Ther. 1989; 46(6).
  • Tornatore KM, Morse GD, Jusko WJ, Walshe JJ. Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression.. Transplantation. 1989; 48(6).
  • Jungbluth GL, Jusko WJ. Ion-paired reversed-phase high-performance liquid chromatography assay for determination of ceftriaxone in human plasma and urine.. J Pharm Sci. 1989; 78(11).
  • Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination.. DICP. 1989; 23(11).
  • Jungbluth GL, Janicke DM, Jusko WJ. Reversed-phase high-performance liquid chromatographic assay for the determination of mezlocillin in human and rat biological samples.. J Chromatogr. 1989; 494.
  • Nichols AI, D'Ambrosio R, Pyszczynski NA, Jusko WJ. Pharmacokinetics and pharmacodynamics of prednisolone in obese rats.. J Pharmacol Exp Ther. 1989; 250(3).
  • Jungbluth GL, Jusko WJ. Dose-dependent pharmacokinetics of mezlocillin in rats.. Antimicrob Agents Chemother. 1989; 33(6).
  • Jusko WJ. Pharmacokinetics of capacity-limited systems.. J Clin Pharmacol. 1989; 29(6).
  • Nichols AI, Boudinot FD, Jusko WJ. Second generation model for prednisolone pharmacodynamics in the rat.. J Pharmacokinet Biopharm. 1989; 17(2).
  • Cheng HY, Jusko WJ. Mean residence time of drugs showing simultaneous first-order and Michaelis-Menten elimination kinetics.. Pharm Res. 1989; 6(3).
  • Cheng H, Jusko WJ. The area function method for assessing the drug absorption rate in linear systems with zero-order input.. Pharm Res. 1989; 6(2).
  • Cheng HY, Jusko WJ. An area function method for calculating the apparent elimination rate constant of a metabolite.. J Pharmacokinet Biopharm. 1989; 17(1).
  • Giacoia GP, Jungbluth GL, Jusko WJ. Effect of formula feeding on oral absorption of caffeine in premature infants.. Dev Pharmacol Ther. 1989; 12(4).
  • Cheng HY, Jusko WJ. Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination.. Pharm Res. 1989; 6(1).
  • Shum L, Jusko WJ. Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding.. Biopharm Drug Dispos. 1989; 10(6).
  • Jungbluth GL, Pasko MT, Jusko WJ. Factors affecting ceftriaxone plasma protein binding during open heart surgery.. J Pharm Sci. 1989; 78(10).
  • Jungbluth GL, Pasko MT, Beam TR, Jusko WJ. Ceftriaxone disposition in open-heart surgery patients.. Antimicrob Agents Chemother. 1989; 33(6).
  • Cheng HY, Jusko WJ. Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination.. Biopharm Drug Dispos. 1989; 10(5).
  • Kong AN, Slaughter RL, Jusko WJ. Simultaneous analysis of methylprednisolone hemisuccinate, cortisol and methylprednisolone by normal-phase high-performance liquid chromatography in human plasma.. J Chromatogr. 1988; 432.
  • Haughey DB, Jusko WJ. Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat.. J Chromatogr. 1988; 430(2).
  • Cheng HY, Jusko WJ. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation.. Pharm Res. 1988; 5(3).
  • Kong AN, Jusko WJ. Definitions and applications of mean transit and residence times in reference to the two-compartment mammillary plasma clearance model.. J Pharm Sci. 1988; 77(2).
  • Sutfin TA, Perini GI, Molnar G, Jusko WJ. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.. J Clin Psychopharmacol. 1988; 8(1).
  • Jungbluth GL, Wirth FH, Rubio TT, Janicke DM, Jusko WJ. Developmental pharmacokinetics of mezlocillin in 4 newborn infants.. Dev Pharmacol Ther. 1988; 11(6).
  • Matsumoto RM, Jusko WJ, Corcoran GB. Hepatic cytochrome P-450 and in vitro drug metabolism in an overfed rat model of obesity.. Drug Nutr Interact. 1988; 5(4).
  • Haughey DB, Jusko WJ. Theophylline disposition in foundry workers exposed to coke oven effluent.. Biopharm Drug Dispos. 1988; 9(4).
  • Kanarkowski R, Tornatore KM, D‘Ambrosio R, Gardner MJ, Yurchak AM, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.. Clin Pharmacol Ther. 1988; 43.
  • Chow AT, Jusko WJ. Application of moment analysis to nonlinear drug disposition described by the Michaelis-Menten equation.. Pharm Res. 1987; 4(1).
  • Gardner MJ, Schatz M, Cousins L, Zeiger R, Middleton E, Jusko WJ. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.. Eur J Clin Pharmacol. 1987; 32(3).
  • Ebling WF, Rich SA, Szefler SJ, Jusko WJ. Troleandomycin effects on methylprednisolone and methylprednisone interconversion and disposition in the rabbit.. Eur J Drug Metab Pharmacokinet. 1987; 12(1).
  • Shum LY, Jusko WJ. Theophylline tissue partitioning and volume of distribution in normal and dietary-induced obese rats.. Biopharm Drug Dispos. 1987; 8(4).
  • Ebling WF, Jusko WJ. The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits.. J Pharmacokinet Biopharm. 1986; 14(6).
  • Jungbluth GL, Cooper DL, Doyle GD, Chudzik GM, Jusko WJ. Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.. Antimicrob Agents Chemother. 1986; 30(6).
  • Shum L, Jusko WJ. Reversed-phase high-performance liquid chromatographic determination of verofylline in rat serum.. J Chromatogr. 1986; 382.
  • Boudinot FD, Jusko WJ. Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats.. J Pharmacokinet Biopharm. 1986; 14(5).
  • Boudinot FD, D'Ambrosio R, Jusko WJ. Receptor-mediated pharmacodynamics of prednisolone in the rat.. J Pharmacokinet Biopharm. 1986; 14(5).
  • Ebling WF, Milsap RL, Szefler SJ, Jusko WJ. 6 alpha-Methylprednisolone and 6 alpha-methylprednisone plasma protein binding in humans and rabbits.. J Pharm Sci. 1986; 75(8).
  • Shum LY, Jusko WJ. Pharmacokinetics of tritiated water in normal and dietary-induced obese rats.. J Pharmacol Methods. 1986; 16(1).
  • Janicke DM, Morse GD, Apicella MA, Jusko WJ, Walshe JJ. Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis.. Clin Pharmacol Ther. 1986; 40(2).
  • Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.. Eur J Clin Pharmacol. 1986; 30(3).
  • Morse G, Janicke D, Cafarell R, Piontek K, Apicella M, Jusko WJ, Walshe J. Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis.. Clin Pharmacol Ther. 1985; 38(2).
  • Boudinot FD, Homon CA, Jusko WJ, Ruelius HW. Protein binding of oxazepam and its glucuronide conjugates to human albumin.. Biochem Pharmacol. 1985; 34(12).
  • Ebling WF, Szefler SJ, Jusko WJ. Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man.. Drug Metab Dispos. 1985; 13(3).
  • Morphy MA, Fava GA, Carson SW, Perini GI, Molnar G, Jusko WJ. The metyrapone test in schizophrenic patients and healthy subjects.. Neuropsychobiology. 1985; 14(1).
  • Janicke DM, Cafarell RF, Parker SW, Apicella MA, Jusko WJ. Pharmacokinetics of aztreonam in patients with gram-negative infections.. Antimicrob Agents Chemother. 1985; 27(1).
  • Milsap RL, Plaisance KI, Jusko WJ. Pharmacokinetics of Prednisolone in Obese Men. Clin Pharmacol Ther. 1984; 36(6).
  • Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia II. Changes upon treatment.. J Affect Disord. 1984; 7(3-4).
  • Boudinot FD, Jusko WJ. Plasma protein binding interaction of prednisone and prednisolone.. J Steroid Biochem. 1984; 21(3).
  • Gengo FM, Schentag JJ, Jusko WJ. Pharmacokinetics of capacity-limited tissue distribution of methicillin in rabbits.. J Pharm Sci. 1984; 73(7).
  • Khalafallah N, Jusko WJ. Tissue distribution of prednisolone in the rabbit.. J Pharmacol Exp Ther. 1984; 229(3).
  • Fava GA, Carson SW, Perini GI, Morphy MA, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia.. J Affect Disord. 1984; 6(3-4).
  • Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.. J Pharm Sci. 1984; 73(6).
  • Lui N, Almon RR, Jusko WJ. Comparison of filtration and equilibrium dialysis methods for [3H]imipramine binding to human platelets.. Anal Biochem. 1984; 139(1).
  • Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in manic patients and healthy subjects.. Pharmacopsychiatry. 1984; 17(3).
  • Janicke DM, Rubio TT, Wirth FH, Karotkin EH, Jusko WJ. Developmental pharmacokinetics of mezlocillin in newborn infants.. J Pediatr. 1984; 104(5).
  • Carson SW, Jusko WJ. Simultaneous analysis of cortexolone and cortisol by high-performance liquid chromatography for use in the metyrapone test.. J Chromatogr. 1984; 306.
  • Khalafallah N, Jusko WJ. Determination and prediction of tissue binding of prednisolone in the rabbit.. J Pharm Sci. 1984; 73(3).
  • Sutfin TA, D'Ambrosio R, Jusko WJ. Liquid-chromatographic determination of eight tri- and tetracyclic antidepressants and their major active metabolites.. Clin Chem. 1984; 30(3).
  • Ebling WF, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis.. J Chromatogr. 1984; 305(2).
  • Shum L, Jusko WJ. Theophylline disposition in obese rats.. J Pharmacol Exp Ther. 1984; 228(2).
  • Gardner MJ, McCarthy TL, Jusko WJ. Relationship of serum thiocyanate concentrations to smoking characteristics.. J Toxicol Environ Health. 1984; 14(2-3).
  • Cuddy ML, Gardner MJ, Mangione A, Yurchak AM, Paigen B, Jusko WJ. Theophylline disposition in residents living near a chemical waste site.. Biopharm Drug Dispos. 1984; 5(4).
  • Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition.. Br J Clin Pharmacol. 1983; 16(3).
  • Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis.. Comput Programs Biomed. 1983; 16(3).
  • Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users.. J Clin Endocrinol Metab. 1983; 56(4).
  • Milsap RL, Jusko WJ. Binding of prednisolone to alpha 1-acid glycoprotein.. J Steroid Biochem. 1983; 18(2).
  • Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ. Effect of inflammatory bowel disease on absorption and disposition of prednisolone.. Dig Dis Sci. 1983; 28(2).
  • Devane CL, Jusko WJ. Drug and metabolite concentrations combined in predicting steady-state concentrations from test doses.. Biopharm Drug Dispos. 1983; 4(1).
  • Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity.. Drug Intell Clin Pharm. 1983; 17(7-8).
  • Rocci ML, Assael BM, Appiani AC, Edefonti A, Jusko WJ. Effect on nephrotic syndrome on absorption and disposition of prednisolone in children.. Int J Pediatr Nephrol. 1982; 3(3).
  • Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination.. Clin Pharmacol Ther. 1982; 32(2).
  • Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, Andrews F, Jusko WJ. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy.. J Allergy Clin Immunol. 1982; 69(5).
  • Jusko WJ, Chiang ST. Distribution volume related to body weight and protein binding.. J Pharm Sci. 1982; 71(4).
  • Pautler DB, Jusko WJ. Determination of metoprolol and alpha-hydroxymetoprolol in plasma by high-performance liquid chromatography.. J Chromatogr. 1982; 228.
  • Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK. Active metabolites of imipramine and desipramine in man.. Clin Pharmacol Ther. 1982; 31(3).
  • Mangione A, Boudinot FD, Schultz RM, Jusko WJ. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.. Antimicrob Agents Chemother. 1982; 21(3).
  • Rocci ML, D'Ambrosio R, Johnson NF, Jusko WJ. Prednisolone binding to albumin and transcortin in the presence of cortisol.. Biochem Pharmacol. 1982; 31(3).
  • Assael BM, Banfi G, Appiani AC, Edefonti A, Jusko WJ. Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome.. Eur J Clin Pharmacol. 1982; 23(5).
  • DeVane CL, Jusko WJ. Dosage regimen design.. Pharmacol Ther. 1982; 17(2).
  • Mangione A, Janicke DM, Boudinot FD, Schultz RM, Jusko WJ. Dose-dependent pharmacokinetics of mezlocillin in subjects with normal and impaired renal function.. J Antimicrob Chemother. 1982; 9 Sup.
  • Clarke DF, George D, Milsap RL, Pogonowska-Wala E, Owerbach J, Lebenthal E, Jusko WJ. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.. Pediatr Pharmacol (New York). 1982; 2(4).
  • Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ, Tornatore KM. Effect of chronic oral contraceptive steroids on theophylline disposition.. Eur J Clin Pharmacol. 1982; 23(2).
  • Gardner MJ, Jusko WJ. Effect of age and sex on theophylline clearance in young subjects.. Pediatr Pharmacol (New York). 1982; 2(2).
  • Meacham RH, Chiang ST, Kick CJ, Sisenwine SF, Jusko WJ, Ruelius HW. Pharmacokinetic disposition of guanabenz in the rhesus monkey.. Drug Metab Dispos. 1982; 9(6).
  • Meacham RH, Chiang ST, Kick CJ, Sisenwine SF, Jusko WJ, Ruelius HW. Pharmacokinetic disposition of guanabenz in the rhesus monkey. Drug Metab Dispos. 1981; 9(6).
  • Rocci ML, Jusko WJ. Dose-dependent protein binding and disposition of prednisolone in rabbits.. J Pharm Sci. 1981; 70(11).
  • Janicke DM, Mangione A, Schultz RW, Jusko WJ. Mezlocillin disposition in chronic hemodialysis patients.. Antimicrob Agents Chemother. 1981; 20(5).
  • Rocci ML, Jusko WJ. Blood collection technique: no effect on in vitro protein binding of prednisolone.. J Pharm Sci. 1981; 70(10).
  • Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man.. J Pharmacokinet Biopharm. 1981; 9(4).
  • DeVane CL, Jusko WJ. Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine.. Drug Intell Clin Pharm. 1981; 15(4).
  • Rose JQ, Nickelsen JA, Ellis EF, Middleton E, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatic children.. J Allergy Clin Immunol. 1981; 67(3).
  • Rose JQ, Yurchak AM, Meikle AW, Jusko WJ. Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.. J Pharmacokinet Biopharm. 1981; 9(1).
  • DeVane CL, Savett M, Jusko WJ. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers.. Eur J Clin Pharmacol. 1981; 19(1).
  • Rocci ML, Szefler SJ, Acara M, Jusko WJ. Prednisolone metabolism and excretion in the isolated perfused rat kidney.. Drug Metab Dispos. 1981; 9(3).
  • Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The Effect of Troleandomycin on Methylprednisolone Disposition. J Allergy Clin Immunol. 1980; 66(6).
  • Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980; 66(6).
  • Rose JQ, Nickelsen JA, Middleton E, Yurchak AM, Park BH, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatics.. J Allergy Clin Immunol. 1980; 66(5).
  • Rocci ML, Johnson NF, Jusko WJ. Prednisolone Serum Protein Binding in Four Species. J Pharm Sci. 1980; 69(8).
  • Lima JJ, Jusko WJ. Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics.. Clin Pharmacol Ther. 1980; 28(2).
  • Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW. Metabolism and Pharmacokinetics of Oxaprozin in Healthy Volunteers. Clin Pharmacol Ther. 1980; 27(3).
  • Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW. Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharmacol Ther. 1980; 27(3).
  • Hilligoss DM, Jusko WJ, Koup JR, Giacoia G, Hart BA. Factors affecting theophylline pharmacokinetics in premature infants with apnea.. Dev Pharmacol Ther. 1980; 1(1).
  • Assael BM, Cavanna G, Jusko WJ, Marini A, Parini R, Sereni F, Viganò A. Multiexponential elimination of gentamicin. A kinetic study during development.. Dev Pharmacol Ther. 1980; 1(2-3).
  • Jusko WJ, Rose JQ. Monitoring prednisone and prednisolone.. Ther Drug Monit. 1980; 2(2).
  • Mackichan JJ, Pyszczynski DR, Jusko WJ. Dose-dependent disposition of oral propranolol in normal subjects.. Biopharm Drug Dispos. 1980; 1(4).
  • Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.. J Pharm Sci. 1979; 68(11).
  • Sutfin TA, Jusko WJ. High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites.. J Pharm Sci. 1979; 68(6).
  • MacKichan JJ, Jusko WJ, Duffner PK, Cohen ME. Liquid-chromatographic assay of diazepam and its major metabolites in plasma.. Clin Chem. 1979; 25(6).
  • MacKichan JJ, Jusko WJ. Hydrocortisone stability in human feces.. J Pharm Sci. 1979; 68(5).
  • Rose JQ, Jusko WJ. Corticosteroid analysis in biological fluids by high-performance liquid chromatography.. J Chromatogr. 1979; 162(3).
  • Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.. J Pharmacokinet Biopharm. 1979; 7(1).
  • Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ. Safety and efficacy of procainamide infusions.. Am J Cardiol. 1979; 43(1).
  • DeVane CL, Wolin RE, Jusko WJ. Pharmacokinetic basis for predicting steady-state serum drug concentrations of imipramine from single dose data.. Commun Psychopharmacol. 1979; 3(5).
  • Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. 1979; 10(4).
  • Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev. 1979; 9(2).
  • Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions.. JAMA. 1978; 240(19).
  • Rose JQ, Barron SA, Jusko WJ. Phenytoin disposition in smokers and nonsmokers.. Int J Clin Pharmacol Biopharm. 1978; 16(11).
  • Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers.. Clin Pharmacol Ther. 1978; 24(4).
  • Owerbach J, Johnson NF, Bates TR, Pieniaszek HJ, Jusko WJ. High-performance liquid chromatographic assay of sulfapyridine and acetylsulfapyridine in biological fluids.. J Pharm Sci. 1978; 67(9).
  • Lima JJ, Conti DR, Goldfarb AL, Golden LH, Jusko WJ. Pharmacokinetic approach to intravenous procainamide therapy.. Eur J Clin Pharmacol. 1978; 13(4).
  • MacKichan JJ, Pyszczynski DR, Jusko WJ. Analysis and disposition of low dose oral propranolol.. Res Commun Chem Pathol Pharmacol. 1978; 20(3).
  • Colburn WA, Schentag JJ, Jusko WJ, Gibaldi M. A model for the prospective identification of the prenephrotoxic state during gentamicin therapy.. J Pharmacokinet Biopharm. 1978; 6(3).
  • Schentag JJ, Lasezkay G, Plaut ME, Jusko WJ, Cumbo TJ. Comparative tissue accumulation of gentamicin and tobramycin in patients.. J Antimicrob Chemother. 1978; 4 Sup.
  • Mangione A, Imhoff TE, Lee RV, Shum LY, Jusko WJ. Pharmacokinetics of theophylline in hepatic disease.. Chest. 1978; 73(5).
  • Gal P, Jusko WJ, Yurchak AM, Franklin BA. Theophylline disposition in obesity.. Clin Pharmacol Ther. 1978; 23(4).
  • Schentag JJ, Lasezkay G, Cumbo TJ, Plaut ME, Jusko WJ. Accumulation pharmacokinetics of tobramycin.. Antimicrob Agents Chemother. 1978; 13(4).
  • Jusko WJ. Role of tobacco smoking in pharmacokinetics.. J Pharmacokinet Biopharm. 1978; 6(1).
  • Lima JJ, Jusko WJ. Determination of procainamide acetylator status.. Clin Pharmacol Ther. 1978; 23(1).
  • Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. 1978; 9(3).
  • Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, Gerbracht LM. Gentamicin disposition and tissue accumulation on multiple dosing.. J Pharmacokinet Biopharm. 1977; 5(6).
  • Resman BH, Blumenthal P, Jusko WJ. Breast milk distribution of theobromine from chocolate.. J Pediatr. 1977; 91(3).
  • Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man.. JAMA. 1977; 238(4).
  • Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, Jusko WJ. Pharmacokinetics of methicillin in patients with cystic fibrosis.. J Infect Dis. 1977; 135(5).
  • Jusko WJ, Koup JR, Vance JW, Schentag JJ, Kuritzky P. Intravenous theophylline therapy: nomogram guidelines.. Ann Intern Med. 1977; 86(4).
  • Gorodischer R, Jusko WJ, Yaffe SJ. Renal clearance of digoxin in young infants.. Res Commun Chem Pathol Pharmacol. 1977; 16(2).
  • Jusko WJ, Poliszczuk A. High-pressure liquid chromatographic and spectrophotometric assays for theophylline in biological fluids.. Am J Hosp Pharm. 1976; 33(11).
  • Jusko WJ, Koup JR, Alván G. Nonlinear assessment of phenytoin bioavailability.. J Pharmacokinet Biopharm. 1976; 4(4).
  • Parsons RL, Jusko WJ, Young JM. Pharmacokinetics of antibiotic absorption in coeliac disease.. J Antimicrob Chemother. 1976; 2(2).
  • Jusko WJ. Drug dosage adjustments in diseased patients.. Ration Drug Ther. 1976; 10(6).
  • Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition.. Clin Pharmacol Ther. 1976; 19(5 Pt).
  • Jusko WJ, Baliah T, Kim KH, Gerbracht LM, Yaffe SJ. Pharmacokinetics of gentamicin during peritoneal dialysis in children.. Kidney Int. 1976; 9(5).
  • Gorodischer R, Jusko WJ, Yaffe SJ. Tissue and erythrocyte distribution of digoxin in infants.. Clin Pharmacol Ther. 1976; 19(3).
  • Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics.. Drug Metab Rev. 1976; 5(1).
  • Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis.. Pediatrics. 1975; 56(6).
  • Koup JR, Jusko WJ, Goldfarb AL. pH-dependent secretion of procainamide into saliva.. J Pharm Sci. 1975; 64(12).
  • Jusko WJ. Ampicillin.. J Am Pharm Assoc. 1975; 15(10).
  • Lewis GP, Jusko WJ. Pharmacokinetics of ampicillin in cirrhosis.. Clin Pharmacol Ther. 1975; 18(4).
  • Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design.. Clin Pharmacol Ther. 1975; 18(1).
  • Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.. J Pharmacokinet Biopharm. 1975; 3(3).
  • Garrettson LK, Jusko WJ. Diphenylhydantoin elimination kinetics in overdosed children.. Clin Pharmacol Ther. 1975; 17(4).
  • Lalka D, Jusko WJ, Bardos TJ. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems II: comparative pharmacokinetics in dogs.. J Pharm Sci. 1975; 64(2).
  • Jusko WJ, Slaunwhite WR, Aceto T. Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man.. J Clin Endocrinol Metab. 1975; 40(2).
  • Jusko WJ, Gerbracht L, Golden LH, Koup JR. Digoxin concentrations in serum and saliva.. Res Commun Chem Pathol Pharmacol. 1975; 10(1).
  • Jusko WJ, Conti DR, Molson A, Kuritzky P, Giller J, Schultz R. Digoxin absorption from tablets and elixir. The effect of radiation-induced malabsorption.. JAMA. 1974; 230(11).
  • Danish M, Schultz R, Jusko WJ. Pharmacokinetics of gentamicin and kanamycin during hemodialysis.. Antimicrob Agents Chemother. 1974; 6(6).
  • Jusko WJ. Proceedings: Prediction of steady-state plasma concentrations of digoxin.. Acta Pharm Suec. 1974; 11(6).
  • Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function.. J Clin Pharmacol. 1974; 14(10).
  • Jusko WJ, Weintraub M. Myocardial distribution of digoxin and renal function.. Clin Pharmacol Ther. 1974; 16(3).
  • Gretch M, Jusko WJ. Letter: Interpretation of drug binding changes in relation to protein concentration.. Br J Anaesth. 1974; 46(7).
  • Szefler SJ, Jusko WJ. Decreased volume of distribution of digoxin in a patient with renal failure.. Res Commun Chem Pathol Pharmacol. 1973; 6(3).
  • Jusko WJ, Gretch M, Gassett R. Precipitation of diazepam from intravenous preparations.. JAMA. 1973; 225(2).
  • Jusko WJ, Lewis GP. Comparison of ampicillin and hetacillin pharmacokinetics in man.. J Pharm Sci. 1973; 62(1).
  • Jusko WJ, Lewis GP, Schmitt GW. Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects.. Clin Pharmacol Ther. 1973; 14(1).
  • Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man.. Cancer Res. 1972; 32(12).
  • Lewis GP, Jusko WJ, Coughlin LL. Cadmium accumulation im man: influence of smoking, occupation, alcoholic habit and disease.. J Chronic Dis. 1972; 25(12).
  • Jusko WJ. Pharmacodynamic principles in chemical teratology: dose-effect relationships.. J Pharmacol Exp Ther. 1972; 183(3).
  • Wizwer P, Lewis GP, Jusko WJ, Slone D. System records drug orders, drug effects.. Hospitals. 1972; 46(18).
  • Jusko WJ, Gibaldi M. Effects of change in elimination on varous parameters of the two-compartment open model.. J Pharm Sci. 1972; 61(8).
  • Jusko WJ, Lewis GP. Precaution in pharmacokinetic evaluation of ampicillin precursors.. Lancet. 1972; 1(7752).
  • Jusko WJ, Lewis GP. Effect of hepatic disease on liver flavin and protein levels.. Am J Clin Nutr. 1972; 25(3).
  • Lewis GP, Coughlin LL, Jusko WJ, Hartz S. Contribution of cigarette smoking to cadmium accumulation in man.. Lancet. 1972; 1(7745).
  • Jusko WJ. Pharmacokinetic principles in pediatric pharmacology.. Pediatr Clin North Am. 1972; 19(1).
  • Jusko WJ, Lewis GP, Dittert LW. Integral coefficients of multi-compartment pharmacokinetic models. Application to chemotherapy.. Chemotherapy. 1972; 17(2).
  • Wizwer P, Lewis GP, Jusko WJ, Slone D. A new system for drug ordering, dispensing and administration in hospitals.. Am J Hosp Pharm. 1972; 29(1).
  • Cohen JL, Jao JY, Jusko WJ. Pharmacokinetics of cyclophosphamide in man.. Br J Pharmacol. 1971; 43(3).
  • Lewis GP, Jusko WJ, Graves L, Burke CW. Prednisone side-effects and serum-protein levels. A collaborative study.. Lancet. 1971; 2(7728).
  • Jusko WJ. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.. J Pharm Sci. 1971; 60(6).
  • Jusko WJ. Fluorometric analysis of ampicillin in biological fluids.. J Pharm Sci. 1971; 60(5).
  • Jusko WJ, Levy G, Yaffe SJ, Allen JE. Riboflavin absorption in children with biliary obstruction.. Am J Dis Child. 1971; 121(1).
  • Jusko WJ, Levy G. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin.. J Pharm Sci. 1970; 59(6).
  • Jusko WJ, Khanna N, Levy G, Stern L, Yaffe SJ. Riboflavin absorption and excretion in the neonate.. Pediatrics. 1970; 45(6).
  • Jusko WJ, Leonards JR, Levy G. Riboflavin distribution and elimination in two functionally anephric human patients.. J Pharm Sci. 1970; 59(4).
  • Jusko WJ, Levy G, Yaffe SJ. Effect of age on intestinal absorption of riboflavin in humans.. J Pharm Sci. 1970; 59(4).
  • Jusko WJ, Levy G, Yaffe SJ, Gorodischer R. Effect of probenecid on renal clearance of riboflavin in man.. J Pharm Sci. 1970; 59(4).
  • Jusko WJ, Rennick BR, Levy G. Renal exretion of riboflavin in the dog.. Am J Physiol. 1970; 218(4).
  • Levy G, Gibaldi M, Jusko WJ. Multicompartment pharmacokinetic models and pharmacologic effects.. J Pharm Sci. 1969; 58(4).
  • Jusko WJ, Levy G. Plasma protein binding of riboflavin and riboflavin-5'-phosphate in man.. J Pharm Sci. 1969; 58(1).
  • Jusko WJ, Levy G. Effect of probenecid on riboflavin absorption and excretion in man.. J Pharm Sci. 1967; 56(9).
  • Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin-5'-phosphate in man.. J Pharm Sci. 1967; 56(1).
  • Levy G, Jusko WJ. Case history of a pharmaceutical formulation failure.. Clin Pharmacol Ther. 1967; 8(6).
  • Levy G, Jusko WJ. Apparent renal tubular secretion of riboflavin in man.. J Pharm Sci. 1966; 55(11).
  • Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man.. J Pharm Sci. 1966; 55(3).
  • LEVY G, JUSKO WJ. EFFECT OF VISCOSITY ON DRUG ABSORPTION.. J Pharm Sci. 1965; 54.
  • Jusko WJ. Influence of cigarette smoking on drug metabolism in man.. Drug Metab Rev. ; 9(2).
  • Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition.. Eur J Clin Pharmacol. ; 23(2).
  • Kong AN, Jungbluth GL, Pasko MT, Beam TR, Jusko WJ. Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass.. Pharmacotherapy. ; 10(1).
  • Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. ; 10(4).
  • Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. ; 9(3).
See All (397 Total) >

Professional Memberships:
  • Phi Lambda Sigma Pharmacy Leadership Society (2002)
  • European Federation for Pharmaceutical Sciences (1999)
  • American College of Clinical Pharmacology (1989)
  • American Association of Pharmaceutical Scientists (1986)
  • American College of Clinical Pharmacy (1980)
  • Federation Internationale Pharmaceutique (1980)
  • American Society for Clinical Pharmacology and Therapeutics (1976)
  • American Society for Microbiology (1975–1994)
  • American Society for Pharmacology and Experimental Therapeutics (1974)
  • American Association for the Advancement of Science (1970)
  • Academy of Pharmaceutical Research and Science (1969)
  • Rho Chi Pharmaceutical Honor Society (1968)
  • Kappa Psi Pharmaceutical Fraternity (1962–1965)
  • American Pharmaceutical Association (1962)
Service Activities:
  • Journal of Pharmacokinetics and Pharmacodynamics; Editor-in-Chief: Journal of Pharmacokinetics and Pharmacodynamics, 2005-present; Editor (2005)
  • Drug Metabolism and Pharmacokinetics (Japan); Editorial Board Member (2002)
  • Food and Drug Administration, CDER; Consultant (1999)
  • Journal of Pharmacology and Experimental Therapeutics; Editorial Board Member (1999)
  • National Institutes of Health, Pharmacology Study Section; Consultant (1997–2001)
  • Pharmacotherapy; Editorial Board Member (1995–2002)
  • Pharmaceutical Research; Editorial Board Member (1995–1997)
  • American Journal of Therapeutics; Editorial Board Member (1994)
  • Journal of Clinical Pharmacology; Editorial Board Member (1993)
  • Journal of Pharmaceutical Sciences; Editorial Board Member (1992–2001)
  • Clinical Pharmacology and Therapeutics; Editorial Board Member (1986)
  • Drug Intelligence and Clinical Pharmacy; Editorial Board Member (1982–1987)
  • Journal of Pharmacokinetics and Biopharmaceutics; Editorial Board Member (1982)
  • Council for International Exchange of Scholars (Fulbright Scholar Program); Medical Sciences Award Committee; Consultant (1980–1984)
  • National Institutes of Health, Pharmacology Study Section; Consultant (1980–1984)
  • Developmental Pharmacology and Therapeutics; Editorial Board Member (1980–1982)
  • Biopharmaceutics and Drug Disposition; Editorial Board Member (1980)
  • Antimicrobial Agents and Chemotherapy; Editorial Board Member (1978–1989)
  • Various pharmaceutical companies; Consultant (1978)
  • Journal of Pharmaceutical Sciences; Editorial Board Member (1976–1981)

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

404 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-2855
Email: wjjusko@buffalo.edu


Log in to Update Your Profile